Disease · MONDO_0000565
Trials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 11 of 11
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03138733 | Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia | Phase 3 | 390 | 2023-05-06 | Staphylococcus Aureus Bacteremia | CEFTOBIPROLE MEDOCARIL SODIUM, DAPTOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT04160468 | Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase | Phase 3 | 259 | 2023-10-18 | Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | EXEBACASE | Its record names the disease | ClinicalTrials.gov |
| NCT04775953 | DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia | Phase 2 | 200 | 2024-10-22 | Staphylococcal Bacteraemia | DALBAVANCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02208063 | A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial | Phase 3 | 121 | 2020-02-17 | Bacteremia | CEFAZOLIN, DAPTOMYCIN, PENICILLIN G POTASSIUM, TELAVANCIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT03148756 | Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis | Phase 2 | 2 | 2018-09-10 | Endocarditis, Bacteremia | DALBAVANCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02701595 | Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus | Phase 3 | 324 | Infective Endocarditis | AMOXICILLIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02701608 | Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus | Phase 3 | 162 | Infective Endocarditis | LEVOFLOXACIN, RIFAMPIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01571791 | Perioperative Ketorolac-lidocaine in the Patients With Valvular Heart Diseases During Cesarean Delivery | Phase 2 | 90 | Valve Heart Disease, Elective Cesarean Delivery | KETOROLAC, LIDOCAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03688659 | Vancomycin, Gentamycin in Infective Endocarditis | Not applicable | 30 | Infective Endocarditis | GENTAMICIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07550595 | Oritavancin for Treatment of Serious Cardiac Infections | Phase 2 | 20 | Infective Endocarditis, Cardiac Device Infection, Gram-positive Bacterial Infections | ORITAVANCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00093067 | Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus | Phase 3 | Bacterial Endocarditis, Bacteremia | DAPTOMYCIN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000565/trials